onartuzumab

Ligand id: 8966

Name: onartuzumab

References
1. Charakidis M, Boyer M. (2014)
Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?.
Transl Lung Cancer Res, 3 (6): 395-6. [PMID:25806331]
2. Huang A, Schwall R, Yansura D. (2005)
Monovalent antibody fragments useful as therapeutics.
Patent number: US20050227324 A1. Assignee: Genentech, Inc.. Priority date: 19/12/2003. Publication date: 13/10/2005.
3. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF. (1997)
Activating mutations for the met tyrosine kinase receptor in human cancer.
Proc. Natl. Acad. Sci. U.S.A., 94 (21): 11445-50. [PMID:9326629]
4. Kong-Beltran M, Wickramasinghe DM. (2009)
Methods and compositions for modulating hyperstabilized c-met.
Patent number: US7615529 B2. Assignee: Genentech, Inc.. Priority date: 05/01/2016. Publication date: 10/11/2009.
5. Meiners S, Brinkmann V, Naundorf H, Birchmeier W. (1998)
Role of morphogenetic factors in metastasis of mammary carcinoma cells.
Oncogene, 16 (1): 9-20. [PMID:9467938]
6. Morley R, Cardenas A, Hawkins P, Suzuki Y, Paton V, Phan SC, Merchant M, Hsu J, Yu W, Xia Q et al.. (2015)
Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program.
PLoS ONE, 10 (10): e0139679. [PMID:26445503]
7. Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. (2015)
Onartuzumab in lung cancer: the fall of Icarus?.
Expert Rev Anticancer Ther, 15 (5): 487-9. [PMID:25818471]